All In Biotech

NDA 012462 · Pfizer

Lomotil

Atropine Sulfate, Diphenoxylate Hydrochloride · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Feb 12, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1960

Sep 15, 1960

Approved uses

1

Original approval plus efficacy supplements

Registered trials

414

74 Phase 3, 30 recruiting

FAERS reports

13,731

9,029 serious, 1,344 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 23, 2026.

INDICATIONS AND USAGE Diphenoxylate hydrochloride and atropine sulfate is indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 15, 1960 Original approval · Type 4 - New Combination · priority review
1 products under this application
  • LOMOTIL · ATROPINE SULFATE 0.025MG; DIPHENOXYLATE HYDROCHLORIDE 2.5MG · TABLET, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Atropine" as an intervention, any sponsor and status, largest first.

All 414 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea2,763
  • nausea1,634
  • fatigue1,495
  • drug ineffective1,136
  • vomiting926
  • weight decreased892
  • pain786
  • dehydration774
  • off label use756
  • abdominal pain749
  • asthenia725
  • headache683

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004219
2005185
2006220
2007211
2008250
2009302
2010333
2011428
2012616
2013574
2014669
20151,093
20161,027
20171,083
20181,119
2019920
2020913
2021722
2022618
2023595
2024582
2025681
2026371

Recalls

1 FDA enforcement reports for this application.

  • Oct 20, 2017 · Class I · Terminated

    SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lomotil (Diphenoxylate HCl/Atropine)

2024 spending

$247K

Beneficiaries

306

773 claims

Per beneficiary

$807

$2.83 per unit

View as table
YearSpending
2020$386,435
2021$325,624
2022$245,868
2023$217,709
2024$246,896

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,896 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.